Monopar Therapeutics Inc. (1IY0)

Overview

Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company based in the United States, focusing on the development of therapeutic solutions for cancer treatments. Founded in 2014 and headquartered in Wilmette, Illinois, the company is dedicated to bringing innovative treatments from the lab to the clinic with the aim of addressing significant unmet medical needs in oncology. Monopar Therapeutics engages in a wide range of research and development activities to create drugs that could potentially improve outcomes for patients suffering from various forms of cancer. Through strategic collaborations with research organizations and medical institutes, Monopar Therapeutics bolsters its R&D capabilities and aims to accelerate the development and clinical testing of its novel drug candidates.

Products and Services

Monopar Therapeutics Inc.'s portfolio includes several promising product candidates in various stages of clinical development:

• Validive (clonidine hydrochloride mucobuccal tablet): Currently in a Phase 2b/3 clinical trial, Validive represents a novel approach for the prevention of chemoradiotherapy-induced severe oral mucositis in patients with oropharyngeal cancer. This condition is a common and painful side effect of cancer treatment, and Validive aims to address this unmet medical need through its unique formulation.
• Camsirubicin: An analog of the chemotherapy agent doxorubicin, Camsirubicin is in a Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma. This drug candidate seeks to provide a treatment option for this aggressive form of cancer, with the potential for reduced cardiotoxicity compared to traditional doxorubicin.
• MNPR-101 (urokinase plasminogen activator receptor targeted antibody): MNPR-101 is being developed for the treatment of various cancers. This targeted antibody has the potential to bind to a specific receptor found in many types of cancer cells, providing a novel mechanism for attacking tumors while sparing healthy tissue.
• MNPR-101 RIT (radioimmunotherapeutic based on MNPR-101): Exploiting the targeting capabilities of MNPR-101, this radioimmunotherapeutic version is designed for the potential treatment of cancers and severe COVID-19. By attaching a radioactive component to MNPR-101, it aims to deliver targeted radiation to cancer cells or infected tissues, reducing the spread and severity of the disease.
• MNPR-202: An analog of Camsirubicin, MNPR-202, is being developed to target doxorubicin- and camsirubicin-resistant cancers. This compound seeks to overcome resistance mechanisms that can make standard treatments ineffective, providing new hope for patients with difficult-to-treat cancers.

In addition to its impressive pipeline of drug candidates, Monopar Therapeutics Inc. has entered into key collaborations to advance the development of its products. Partnerships with the Grupo Español de Investigación en Sarcomas, NorthStar Medical Radioisotopes, LLC, and the Cancer Science Institute of Singapore highlight the company’s commitment to leveraging external expertise and resources to bring its innovative cancer therapies closer to clinical application.